H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Hookipa Pharma to $6 from $5 and keeps a Buy rating on the shares. Hookipa presented additional positive data from its Phase 2 study evaluating HB-200 plus pembrolizumab as first-line treatment of recurrent/metastatic human papillomavirus 16 positive head and neck squamous cell carcinoma, the analyst tells investors in a research note. The firm believes HB-200 plus pembrolizumab have a high likelihood to outperform placebo plus pembrolizumab in its planned Phase 2/3 pivotal study. It increased its probability of launch of HB-200 to 70% from 50%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOOK:
- Hookipa Pharma’s HB-200 Shows Promise in Phase 2 Cancer Trial
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
- HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
- Hookipa Pharma announces updated HB-200 trial results
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue